A Synbiotic for the Oral–Nasal Gateway: The Mechanistic Rationale, Pathogen-Targeting Profile, and Implications for Gut and Pulmonary Health

The oral cavity and the nasal passage form a single, continuously mixed ecological gateway rather than two independent niches: saliva is swallowed roughly once every one to two minutes while awake, and nasal mucus is transported posteriorly into the nasopharynx on a cycle of roughly ten to twenty minutes, so oral and nasal microbial communities are in near-constant fluid exchange with each other and with the gut. This narrative review examines the mechanistic rationale for a proposed formulation containing Streptococcus salivarius M18, Lactobacillus plantarum HEAL9, Lacticaseibacillus paracasei 8700:2, and Bifidobacterium longum subsp. infantis, with 2 g/day xylitol and vitamins C and D3. We assess component-level evidence for bacteriocin-mediated antagonism, immune modulation, colonization resistance, and airway-surface effects and relate these findings to oral–gut translocation, lung microbiome seeding, and gut–lung immune signaling. The strongest clinical support concerns caries-related and upper respiratory outcomes for individual components or strain pairs. Gut effects depend on strain identity, age, diet, and substrate availability; pulmonary benefits remain indirect hypotheses. No trial has tested the complete formulation, and evidence from topical nasal xylitol cannot establish nasal efficacy after oral administration. Cardiovascular findings involving circulating xylitol and experimental platelet activation warrant dose-specific safety evaluation; their relevance to 2 g/day remains uncertain. Trials should establish strain identity, compatibility, viability, and safety, then pair clinical endpoints with longitudinal oral, nasal, and intestinal sampling. The proposed formulation offers a testable approach to the oral–nasal–gut–pulmonary axis, but its efficacy and safety require product-specific confirmation.